US 12,589,160 B2Granted

Peptide-derived therapeutics targeting KDM5C for the treatment of cancer

AssigneeNuvobio Corporation

InventorsKyle Kevin Biggar, Hemanta Adhikary, Matthew Jacob Hoekstra

Life of this patent

Estimating the term…

Abstract

The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind KDM5C for the treatment of cancer.

Claims6

Dependent claims

A peptide that binds to KDM5C and consists of the sequence selected from the group consisting of T D T T K T H H H (SEQ ID NO:1);

T D T Q K T H H H (SEQ ID NO:2);
T D T N K T H H H (SEQ ID NO:3);
T E D Q K T H H H (SEQ ID NO:5);
T T Q S K T H H H (SEQ ID NO:6);
T D T S K T H H H (SEQ ID NO:7);
TED TK THHH (SEQ ID NO:8);
S D Q Q K T H H H (SEQ ID NO:10);
T T Q Q K T H H H (SEQ ID NO:11);
S D Q T K T H H H (SEQ ID NO:12);
T D D Q K T H H H (SEQ ID NO:13);
T E E N K T H H H (SEQ ID NO:14);
T E E S K T H H H (SEQ ID NO:15);
T T Q T K T H H H (SEQ ID NO:16);
T D S T K T H H H (SEQ ID NO:17);
S E T Q K T H H H (SEQ ID NO:18);
S E T S K T H H H (SEQ ID NO:19);
T D D N K T H H H (SEQ ID NO:20);
T D T T n T H H H (SEQ ID NO:21);
T D T Q n T H H H (SEQ ID NO:22);
T D T N n T H H H (SEQ ID NO:23);
T E D S n T H H H (SEQ ID NO:24);
T E D Q n T H H H (SEQ ID NO:25);
T T Q S n T H H H (SEQ ID NO:26);
T D T S n T H H H (SEQ ID NO:27);
T E D T n T H H H (SEQ ID NO:28);
T E E Q n T H H H (SEQ ID NO:29);
S D Q Q n T H H H (SEQ ID NO:30);
T T Q Q n T H H H (SEQ ID NO:31);
S D Q T n T H H H (SEQ ID NO:32);
T D D Q n T H H H (SEQ ID NO:33);
T E E N n T H H H (SEQ ID NO:34);
T E E S n T H H H (SEQ ID NO:35);
T T Q T n T H H H (SEQ ID NO:36);
T D S T n T H H H (SEQ ID NO:37);
S E T Q n T H H H (SEQ ID NO:38);
S E T S n T H H H (SEQ ID NO:39);
T D D N n T H H H (SEQ ID NO:40);
R T K Q T A R K S T G G (SEQ ID NO:41);
R T n Q T A R K S T G G (SEQ ID NO:42);
G A K R H R K V L R D N I (SEQ ID NO:43) and GA K R H R n V L R D N I (SEQ ID NO:44);
wherein n=norLeucine (Nle) or a binding fragment thereof.

38 more elements

A peptide consisting of the sequence selected from the group consisting of:

(SEQ ID NO:
23)
TDTNnTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
2)
TDTQKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
3)
TDTNKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
27)
TDTSnTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
4)
TEDSKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
7)
TDTSKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
40)
TDTTnTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
25)
TEDQnTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
6)
TTQSKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
5)
TEDQKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
44)
GAKRHRnVLRDNI
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
38)
SETQnTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
10)
SDQQKTHHH
(SEQ ID NO:
45)
{6-aminohexanoic acid}GRKKRRQRRRPPQ;
(SEQ ID NO:
23)
TDTNnTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
2)
TDTQKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
3)
TDTNKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
27)
TDTSnTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
4)
TEDSKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
7)
TDTSKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
40)
TDTTnTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:)
TEDQnTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
6)
TTQSKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
5)
TEDQKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
44)
GAKRHRnVLRDNI
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
38)
SETQnTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
10)
SDQQKTHHH
(SEQ ID NO:
49)
{6-aminohexanoic acid}FFLIPKGRRRRRRRRR;
(SEQ ID NO:
23)
TDTNnTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
2)
TDTQKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
3)
TDTNKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
27)
TDTSnTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
4)
TEDSKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
7)
TDTSKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
40)
TDTTnTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:)
TEDQnTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
6)
TTQSKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
5)
TEDQKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
44)
GAKRHRnVLRDNI
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
(SEQ ID NO:
38)
SETQnTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR;
and
(SEQ ID NO:
10)
SDQQKTHHH
(SEQ ID NO:
50)
{6-aminohexanoic acid}RRWRRWRRWRR.

230 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/438,925Filed 12 Mar 2020 · us provisional application
Priority: 15 Mar 2019
Published: US 2022/0184221 A116 Jun 2022
Granted: 31 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 47/645
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…:…
A61P 35/00
Antineoplastic agents
C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids

Family

Application62/818,793Us provisional application · filed 15 Mar 2019
US 2022/0184221 A1Pre-grant publication · published 16 Jun 2022
US 12,589,160 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind KDM5C for the treatment of cancer.

Facts

Application

17/438,925Filed 12 Mar 2020 · us provisional application

Priority

15 Mar 2019

Published

US 2022/0184221 A116 Jun 2022

Granted

31 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 47/645
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…:…
A61P 35/00
Antineoplastic agents
C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids